Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma‐derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients ha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: van Velzen, Alice S., Eckhardt, Corien L., Peters, Marjolein, Oldenburg, Johannes, Cnossen, Marjon, Liesner, Ri, Morfini, Massimo, Castaman, Giancarlo, McRae, Simon, van der Bom, Johanna G., Fijnvandraat, Karin
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Platelets, Haemostasis and Thrombosis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318706/
https://ncbi.nlm.nih.gov/pubmed/32201943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16490
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars